|
|
 |
|
Viewing report
|
|
|
|
The Asthma and COPD Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Business Insights, Jan 2005
In terms of revenue, the asthma and COPD therapeutic area historically ranks as the sixth largest single source of sales for the pharmaceutical industry. The outlook for the market is currently strong, driven by strategically sound lifecycle management from the major players in the asthma and COPD area, new product launches and favourable epidemiology. Generic competition will continue to remain the major threat to sales growth in this market. 'The Asthma and COPD Market Outlook: Market Analysis of Future Growth and Leading Players by Sector' provides detailed analysis of all classes of asthma and chronic obstructive pulmonary disease (COPD) drugs across all major indications. Forecasts are provided over the period 2004-2009, enabling you to identify the market leaders of the future and spot potential opportunities and threats to your market position.
This report provides:
- Detailed analysis of current market dynamics in the asthma and COPD sectors for 2003 across all major brands and classes of drugs.
- Performance analysis of the leading brands in six geographic markets including the US, UK, France, Italy, Germany, and Spain.
- Company analysis and market share of the top players in the asthma and COPD sectors, including GlaxoSmithKline, AstraZeneca, Merck, Boehringer Ingelheim, Schering-Plough, Novartis and Sepracor.
- Epidemiological analysis and forecasts in asthma and COPD indications across the seven largest geographic pharmaceutical markets.
- Analysis of future high-potential launches and the R&D pipelines of the largest players in the asthma and COPD area.
Actionable strategies to drive your profits forward
- Understand which brands have the greatest potential to develop market share, and how major players are attempting to exploit these opportunities.
- Save valuable time and research budget with the report's coverage of all the major indications in the asthma/COPD area, the six largest geographic pharmaceutical markets and the largest companies active in the asthma/COPD area today.
- Use head-to head comparisons of the asthma/COPD pipelines of leading players to understand which companies are likely to be the market leaders in key indications over the next 5 years.
- Quickly analyze how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the asthma/COPD marketplace.
- Compare the franchises of top pharmaceutical marketers across the asthma/COPD sector, and understand how the market share of leading companies will change over the next 6 years.
Hot issues covered in this report
Success of combination therapies has repercussions on the first/second-line asthma market: The strong performance of combination corticosteroid/beta-2 agonist therapies has repercussions for the long-term prospects of monotherapies, which are already under pressure from generic competition.
Can Symbicort break Seretide/Advair's dominant market position in the US? : The runaway success of Seretide/Advair in the US, where it has been the only available monotherapy, is likely to end in 2005 providing AstraZeneca can solve difficulties it has faced in developing an appropriate inhaler for Symbicort. However, with such an obvious lead in market share, AstraZeneca may look to competing on the basis of price and superiority in pediatric indications.
Spiriva looks set to change COPD treatment: Boehringer Ingelheim's Spiriva provides an efficacious first-line treatment for COPD, that is set to negatively impact sales of existing bronchodilators that are traditionally used in first-line therapy. Spiriva's current success is likely to enable Boehringer
Ingelheim to shut the door to competitors through the company's dominant control of first and second-line treatments: Novel therapies thus far appear to offer few breakthroughs in treatment Genentech's Xolair and GSK's Ariflo are long-awaited new treatments for asthma and COPD but their clinical benefit over existing treatments is limited in comparison to their significantly higher price point. Such novel treatments launched at premium prices are likely to target niche market segments such as hard-to-treat and paediatric populations.
Your questions answered
- Which were the best performing asthma and COPD brands in Europe and the US?
- Which categories of treatments performed the strongest?
- Which companies have the strongest asthma and COPD R&D pipelines?
- What has been the impact of generic competition on first and second-line therapies?
- Which companies were the strongest performing and why?
- How have recently launched medicines Symbicort and Spiriva performed?
- How is the epidemiology of asthma and COPD and the way in which these diseases are treated likely to change in the future?
|
|
|
|
